<DOC>
	<DOC>NCT00395577</DOC>
	<brief_summary>The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.</brief_summary>
	<brief_title>A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients 18 to 75 years of age with active RA Must have been taking MTX for at least 6 months No concurrent DMARD treatment (other than a stable dose of MTX) Planned major surgery (e.g., joint replacement) within the duration of the treatment period of the study Treated with intraarticular injections of corticosteroids within 28 days prior to Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>